Compare Stocks → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATNFNASDAQ:BIVINASDAQ:CRBPNASDAQ:ITRMNASDAQ:NEPT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNF180 Life Sciences$1.99+10.6%$2.99$1.33▼$27.93$1.69M0.44108,548 shs25,396 shsBIVIBioVie$0.48+0.3%$0.78$0.45▼$8.69$19.35M0.82.15 million shs237,785 shsCRBPCorbus Pharmaceuticals$39.38+4.5%$35.57$3.03▼$49.87$413.88M2.45789,786 shs114,005 shsITRMIterum Therapeutics$1.56-1.2%$1.51$0.62▼$2.50$25.64M2.36513,193 shs23,451 shsNEPTNeptune Wellness Solutions$0.39$0.19▼$28.00$906K2.19462,687 shs2.25 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNF180 Life Sciences-1.10%-10.89%-35.02%-55.12%-92.04%BIVIBioVie-0.68%-1.93%-16.05%-48.04%-93.84%CRBPCorbus Pharmaceuticals-3.92%-11.75%+7.90%+416.44%+326.47%ITRMIterum Therapeutics+8.39%+0.65%-3.13%-22.11%+44.86%NEPTNeptune Wellness Solutions0.00%0.00%0.00%-57.67%-99.26%Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside himMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNF180 Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ABIVIBioVie1.3915 of 5 stars3.34.00.00.02.40.00.0CRBPCorbus Pharmaceuticals4.4629 of 5 stars3.53.00.04.72.93.30.6ITRMIterum Therapeutics0.8758 of 5 stars3.52.00.00.00.60.00.6NEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNF180 Life SciencesN/AN/AN/AN/ABIVIBioVie2.50Moderate Buy$8.001,550.85% UpsideCRBPCorbus Pharmaceuticals3.00Buy$52.0032.05% UpsideITRMIterum Therapeutics3.00Buy$6.00284.47% UpsideNEPTNeptune Wellness SolutionsN/AN/AN/AN/ACurrent Analyst RatingsLatest CRBP, NEPT, BIVI, ITRM, and ATNF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/13/2024CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$51.00 ➝ $58.003/6/2024CRBPCorbus PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$4.00 ➝ $46.003/6/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.002/7/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$6.001/29/2024CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$20.00 ➝ $51.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNF180 Life SciencesN/AN/AN/AN/A($0.24) per shareN/ABIVIBioVieN/AN/AN/AN/A$0.42 per shareN/ACRBPCorbus Pharmaceuticals$880K470.32N/AN/A($1.56) per share-25.24ITRMIterum TherapeuticsN/AN/AN/AN/A($0.48) per shareN/ANEPTNeptune Wellness Solutions$52.62M0.00N/AN/A($91.90) per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNF180 Life Sciences-$19.93MN/A0.00∞N/AN/A-320.26%-112.07%5/20/2024 (Estimated)BIVIBioVie-$50.26M-$1.17N/A∞N/AN/A-332.18%-137.85%5/10/2024 (Estimated)CRBPCorbus Pharmaceuticals-$44.60M-$10.37N/AN/AN/AN/A-920.31%-111.56%5/14/2024 (Estimated)ITRMIterum Therapeutics-$38.37M-$2.97N/AN/AN/AN/A-664.00%-87.64%5/10/2024 (Estimated)NEPTNeptune Wellness Solutions-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%7/15/2024 (Estimated)Latest CRBP, NEPT, BIVI, ITRM, and ATNF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/23/2024N/ABIVIBioVieN/A-$0.33-$0.33N/AN/AN/A3/28/2024Q4 2023ITRMIterum Therapeutics-$1.02-$0.94+$0.08-$0.94N/AN/A3/12/2024Q4 2023CRBPCorbus Pharmaceuticals-$2.36-$1.81+$0.55-$1.81N/AN/A2/12/2024Q2 2024BIVIBioVie-$0.32-$0.22+$0.10-$0.22N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNF180 Life SciencesN/AN/AN/AN/AN/ABIVIBioVieN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNF180 Life SciencesN/A0.720.72BIVIBioVieN/A1.471.47CRBPCorbus PharmaceuticalsN/A0.740.74ITRMIterum Therapeutics3.631.891.89NEPTNeptune Wellness SolutionsN/A0.230.10OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNF180 Life Sciences4.07%BIVIBioVie4.59%CRBPCorbus Pharmaceuticals64.64%ITRMIterum Therapeutics9.21%NEPTNeptune Wellness Solutions14.44%Insider OwnershipCompanyInsider OwnershipATNF180 Life Sciences4.10%BIVIBioVie4.80%CRBPCorbus Pharmaceuticals4.00%ITRMIterum Therapeutics5.40%NEPTNeptune Wellness Solutions5.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATNF180 Life Sciences5850,000818,000No DataBIVIBioVie1839.92 million38.01 millionOptionableCRBPCorbus Pharmaceuticals1910.51 million10.09 millionOptionableITRMIterum Therapeutics1416.43 million15.54 millionNot OptionableNEPTNeptune Wellness Solutions584.53 million4.30 millionNot OptionableCRBP, NEPT, BIVI, ITRM, and ATNF HeadlinesSourceHeadlineNeptune Wellness Solutions (NASDAQ:NEPT) Now Covered by Analysts at StockNews.comamericanbankingnews.com - April 16 at 2:22 AMNeptune prepared to take legal action against property owner of the homeless encampmentmsn.com - April 9 at 2:18 PMCity of Neptune Beach unveils new water tower designmsn.com - April 7 at 1:48 PMGunbattle between Haitian police and gangs paralyzes area near National Palacesaratogian.com - April 2 at 1:45 AMThe Wellness Innovation Summit at the Knoxville Convention Center Saturday, April 6thwate.com - April 1 at 10:44 AMSNAPSHOT: Construction supervisor credits BOCES with building him a solid foundation for his futuresaratogian.com - April 1 at 10:44 AMWellness Wednesday – Focusing on Cardiovascular Healthnwahomepage.com - March 28 at 6:30 PMFood Encapsulation Market Industry Chain Information, Emerging Market Regions (2024-2032)taiwannews.com.tw - March 28 at 6:30 PMSNAPSHOT: The Bunker celebrates opening of newest location in Saratoga Springssaratogian.com - March 25 at 8:40 AMSNAPSHOT: Capital Region BOCES event will link students to employers and recruiterssaratogian.com - March 24 at 9:05 AMKingdom Wellness & Dispensary opens new retail locationwestsidenewsny.com - March 18 at 12:39 PMWellness expo promotes better health within Black familiesksdk.com - March 17 at 8:17 PMRooted Wellness celebrates grand openinglowellsun.com - March 15 at 8:16 PMClinton to host Mayor's Wellness Program on Saturday, March 23newjerseyhills.com - March 15 at 3:15 PMYour Weekly Horoscopes: March 17 to 23, 2024purewow.com - March 15 at 12:13 AMHealthwise Wellness hosts clinic open housearkansasonline.com - March 13 at 7:38 AMSouthwell Center for Healing and Wellness to permanently closemsn.com - March 12 at 12:26 AMNeptune Software: 'Environmental Supply Chains - You Don't Need to Sacrifice Profitability to Act Sustainably'tmcnet.com - March 11 at 2:25 PMNeptune Wellness Solutions Inc.wsj.com - March 9 at 8:59 AMNeptune Wellness appoints Michael De Geus as interim president, CEOmsn.com - March 8 at 9:40 AMNeptune Appoints Interim President and CEO and Interim COOaccesswire.com - March 8 at 8:30 AMNeptune Wellness to be delisted from Nasdaqinvesting.com - March 8 at 12:42 AMTop Marijuana Stocks For Trading Today 2024marijuanastocks.com - March 6 at 9:06 AMNeptune Announces Decision of Nasdaq Hearings Panel To Delist Common Sharesaccesswire.com - March 6 at 8:30 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany Descriptions180 Life SciencesNASDAQ:ATNF180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.BioVieNASDAQ:BIVIBioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.Corbus PharmaceuticalsNASDAQ:CRBPCorbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Iterum TherapeuticsNASDAQ:ITRMIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Neptune Wellness SolutionsNASDAQ:NEPTNeptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.